Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study

OBJECTIVE: To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis. METHODS: At baseline, patients with active ankylosing spondylitis (n=356) were randomly assigned (1:1.8:1.8) to subcutaneous injections of placebo (group 1), golimumab 50 mg (grou...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Braun, Jürgen, Deodhar, Atul, Inman, Robert D, van der Heijde, Désirée, Mack, Michael, Xu, Stephen, Hsu, Benjamin
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2011
Assuntos:
Clinical and Epidemiological Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3329230/
https://ncbi.nlm.nih.gov/pubmed/22012970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2011.154799
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados